Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine... (

HOME >> MEDICINE >> TECHNOLOGY

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction

Date:1/25/2008

- Additional Clinical Trial Sites To Be Added -

- Fast Track Status With FDA -

CORAL GABLES, Fla., Jan. 25 /PRNewswire-FirstCall/ -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX), a biopharmaceutical company that acquires, in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction, today announced that it has initiated enrollment of patients for its 180- patient, U.S. Phase II clinical trial evaluating the use of CPP-109 in treating patients with cocaine addiction. CPP-109, an orally administered, small molecule drug which inhibits psychostimulant-induced dopamine release, is Catalyst's lead compound, vigabatrin.

The Phase II trial is designed as a randomized, double-blind, placebo- controlled, intent-to-treat, multi-center study to evaluate the safety and efficacy of CPP-109 as a treatment for cocaine addiction. Under the study protocol, patients will be treated for a period of 12 weeks, with an additional 12 weeks of follow-up. The primary objective of the study is to demonstrate that a larger proportion of CPP-109-treated subjects than placebo- treated subjects are cocaine-free during their last two weeks of treatment (weeks 11 and 12). Additionally, Catalyst will be measuring a number of secondary endpoints based on reductions of cocaine use and craving.

Catalyst's web site http://www.catalystpharma.com includes a listing of the CPP- 109 study sites and relevant contact information. For more information about enrolling in this study, please contact the study sites directly. Additional detailed information can be found on http
'/>"/>

SOURCE Catalyst Pharmaceutical Partners, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
3. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
4. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
5. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
6. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
7. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
8. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
9. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation

Post Your Comments:

(Date:12/16/2009)... Dec. 16 Savara, Inc., an inhalation drug ... second tranche in its Series A financing round, exceeding ... ,, Funds raised in the Series A round ... NanoCluster technology. ,, "We now have the runway ... of the NanoCluster technology," said Rob Neville, CEO of ...

(Date:12/16/2009)... Dec. 16 ChemoCentryx, Inc. today announced ... Phase 2 clinical trial of CCX354, an orally-bioavailable, ... the CCR1 chemokine receptor for the treatment of ... highly potent and selective antagonist of CCR1, a ... cells, such as monocytes and macrophages, associated with ...

(Date:12/16/2009)... -- , - ... a Total of Over,640 patients Ahead of ... NV (Euronext Brussels: THR), a biopharmaceutical company,focused ... treatments for eye,disease, vascular disease and cancer, ... of the second Phase III trial evaluating ...

[0] Savara Closes Second Tranche of Series A Financing Round, Receives Allowance for Base Patent [0] ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis [0] ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease

... is an urgent need for more,comprehensive lipid control to ... A new 30-year analysis of the,National Health and ... Association (NLA) indicates that while,Americans are doing a better ... adults with high triglycerides, a blood fat linked to ...

... Data from an investigational,open-label, randomized study assessing ... treating anemia in subjects with Stages 3 ... today at the American Society,of Nephrology 41st ... including the FDA-approved,three-times-per-week (TIW) regimen, plus once-a-week ...

Other Medicine Technology:New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 2 New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 2 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 3 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 4 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 5 Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting 6

New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity Data From Investigational Use of PROCRIT(R) (Epoetin alfa) Presented at American Society of Nephrology Annual Meeting

(Date:12/16/2009)... 16 Shoppers like knowing if their ... Argentina. But grocers have found it burdensome to ... laws requiring them to provide the information at ... easyCOOLnow.com for easily making grocery and ... provisions that require retailers of unprocessed fruits, vegetables ...

(Date:12/16/2009)... 16 A new software program developed by ... healthcare facilities to calculate their staffing needs as it ... allows inpatient healthcare facilities to calculate their mandatory ... ratios and receive a daily report as to how ... a leader in risk management in the healthcare industry, ...

(Date:12/16/2009)... In a random sampling of wood pallets used ... PA, numerous pallets tested positive for Listeria and ... create health hazards for consumers. The new ... testing conducted in the Washington-Baltimore area, further illustrating ... nation,s food supply from wood pallets. ,, The ...

(Date:12/16/2009)... procedures in cardiology. The idea of publishing an ESC ... European cardiovascular imagers, is therefore long awaited. The textbook ... a patient rather than technology-based approach, helping clinicians to ... of imaging. , The book is divided into ... of cardiac imaging and its clinical use in all ...

(Date:12/16/2009)... happens when the families of sick and dying hospitalized ... for them? How do pediatricians respond to such personal ... and spirituality help some patients and families cope with ... almost always the families and patients who raise the ... the current issue of Southern Medical Journal , ...

Breaking Medicine News(10 mins):Health News:New Website Helps Grocers Comply With COOL Laws 2 Health News:United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software 2 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 2 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 3 Health News:New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria 4 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 2 Health News:The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center 3 Health News:Prayer on the hospital floor 2

[0] New Website Helps Grocers Comply With COOL Laws [0] United States Patent Office Allows CareRise Patent on 24/7 Staff-Census Software [0] New Tests Confirm Wood Pallets Harbor Deadly Food Poisoning Bacteria [0] The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center [0] Prayer on the hospital floor

... underreport the number of hot flashes that they experience by ... to poor verbal memory, according to a study by researchers ... is published online and will appear in the September/October issue ... first study to explore the relationship between objectively measured hot ...

... especially, the brew could boost heart health, study finds , , ... lovers: Drinking up to six cups a day of caffeinated ... new study shows. , In fact, coffee might even help ... results suggest that long-term, regular coffee consumption does not increase ...

... 16 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or the ... provider of,pharmacy benefits management services, announces that effective June ... Executive Officer (CEO),will retire from the position of CEO, ... Officer, will be appointed President and CEO.,Both will continue ...

... EDEN PRAIRIE, Minn., June 16 Through emotional ... Benatar and,Neil Giraldo helped the Starkey Hearing Foundation, ... a record $5,045,000 at its annual,"So the World ... at the,RiverCentre in Saint Paul, Minn. With money ...

... MELVILLE, N.Y., June 16 The Hain Celestial,Group, Inc. ... food and personal,care products company, today announced that Irwin ... NASDAQ Stock Market Opening Bell on,Wednesday, June 18th at ... been nearly 15 years since The Hain Celestial Group ...

... medicine in the 19th,& 20th century, Behavioral Medicine will take ... component of Behavioral Medicine, Dr. John ... Basmajian, Member of the Order of Canada, MONTREAL, ... trained Canada,s top Olympic athletes will be teaching a,workshop in ...

Other Medicine News:Health News:Hot flashes underreported and linked to forgetfulness 2 Health News:Coffee Drinkers Might Live Longer 2 Health News:Coffee Drinkers Might Live Longer 3 Health News:SXC Health Solutions announces Mark Thierer to be named President & CEO 2 Health News:Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser 2 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 2 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 3 Health News:Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM) 4 Health News:Biofeedback Workshops & Distance Learning Offer Credits and Training Options 2

Hot flashes underreported and linked to forgetfulness Coffee Drinkers Might Live Longer SXC Health Solutions announces Mark Thierer to be named President & CEO Garth Brooks, Jon McLaughlin, and Pat Benatar and Neil Giraldo Raise Their Voices to Help Starkey Hearing Foundation Raise More Than $5 Million at Annual Fundraiser Hain Celestial to Open The NASDAQ Stock Market and Celebrate Summer With A Healthy Way of Life(TM)Biofeedback Workshops & Distance Learning Offer Credits and Training Options

The Bio-Quant TROPONIN I test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of cardiac,troponin I (cTnI) in human serum specimens as an aid i...

... InstaTest IgE test kit is an immunochromatographic ... levels of immunoglobulin E in human serum ... commonly associated with allergic pathologies. It may ... some infections. Rapid detection of IgE using ...

... is an all new, completely re-engineered high performance ... LOWEST CROSSING PROFILE PTCA products available ... profile of only 0.17. Atriums all new HyperLite ... catheter ever!, ,Atriums new "Dura-Blend tip technology is ...

... The Veris physiological monitor offers a ... those specifically designed for pediatric and neonate ... up to 3T. Veris is the first ... needs of pediatric and neonate patient monitoring. ...

Medicine Products:

Troponin I - Rapid Test IgE - Rapid Test Kit HyperLite LX Veris MR Vital Signs Monitor

Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine...( - Additional Clinical T...),Health